Henny C P, Ten Cate H, Ten Cate J W, Surachno S, van Bronswijk H, Wilmink J M, Ockelford P A
Lancet. 1983 Apr 23;1(8330):890-3. doi: 10.1016/s0140-6736(83)91326-0.
Org 10172, a new, natural heparinoid, was used as the sole anticoagulant in twelve patients with acute or acute-on-chronic renal failure, who underwent haemodialysis 55 times. All patients had either intercurrent bleeding or a high risk of severe haemorrhagic complications if given standard heparin therapy. After a single loading dose of 300-600 mg of Org 10172, plasma anti-Xa levels in the range 0.42 - 0.93 U/ml were achieved. All haemodialysis runs were completed without adverse side-effects. There were no haemorrhagic complications and deposition of 125I-fibrinogen on the renal dialysis membrane was successfully inhibited in the 4 patients in whom this was studied. Org 10172 seems to prevent thrombosis during renal haemodialysis. It may have a lower risk/benefit ratio than other anticoagulants, such as heparin, in patients at high risk of haemorrhagic complications undergoing haemodialysis.
Org 10172是一种新型天然类肝素，在12例急性或慢性肾衰竭急性发作患者中作为唯一的抗凝剂使用，这些患者共接受了55次血液透析。如果给予标准肝素治疗，所有患者均有并发出血或严重出血并发症的高风险。在单次给予300 - 600 mg Org 10172负荷剂量后，血浆抗Xa水平达到0.42 - 0.93 U/ml。所有血液透析过程均顺利完成，无不良副作用。无出血并发症发生，在研究的4例患者中，成功抑制了125I-纤维蛋白原在肾透析膜上的沉积。Org 10172似乎可预防肾血液透析期间的血栓形成。对于接受血液透析且有出血并发症高风险的患者，它可能比其他抗凝剂（如肝素）具有更低的风险/效益比。
